Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
Holding IMVT?
Track your performance easily
IMVT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.50 - $45.58
Previous Close$29.59
Volume1.96M
Average Volume (3M)1.03M
Market Cap
$4.33B
Enterprise Value$3.77B
Total Cash (Recent Filing)$560.00M
Total Debt (Recent Filing)$69.00K
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Nov 01, 2024EPS Estimate
-$0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding146,367,374
10 Day Avg. Volume1,245,080
30 Day Avg. Volume1,034,489
Standard Deviation0.24
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)7.95
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-12.20
Forecast
1Y Price Target
$49.46Price Target Upside69.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Immunovant News
PremiumCompany Announcements
Immunovant Advances Groundbreaking Therapy in Graves’ Disease Trials
Bulls Say, Bears Say
Bulls Say
EfficacyTreatment with 680mg bato weekly led to a highly compelling 76% response rate, well above the ~50% response rate IMVT highlighted as their clinically relevant bar for success.
Market OpportunityNew epidemiologic analyses suggest that the Graves’ market opportunity is sufficiently large, with ~330K prevalent and ~20K incident Graves’ patients uncontrolled on ATD therapy.
SafetyBato was generally safe and well tolerated, with all treatment-emergent adverse events characterized as mild-to-moderate in severity, and no treatment-related serious adverse events observed.
Bears Say
Clinical TrialsArgenx will not advance the development of efgartigimod in post-COVID-19-mediated postural orthostatic tachycardia syndrome (PC-POTS) based on negative data from its Phase 2 study; this was considered to be relatively risky.
Financial PerformanceImmunovant posted a loss per share of $0.60 in 1Q25, slightly worse than our estimate of $0.57 loss per share and the consensus of $0.53 loss per share.
Market SentimentThe data may have been priced in and is being viewed as 'sell the news.'
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $19.50 and its highest was $45.58 in the past 12 months.
What is Immunovant’s market cap?
Currently, no data Available
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Nov 01, 2024 which is in 42 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Aug 06, 2024. The company reported -$0.527 earnings per share for the quarter, missing the consensus estimate of -$0.524 by -$0.003.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -$0.59.
How many shares outstanding does Immunovant have?
Immunovant has 146,367,370 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.527 in its last earnings report, missing expectations of -$0.524. Following the earnings report the stock price went down -3.124%.
Which hedge fund is a major shareholder of Immunovant?
Among the largest hedge funds holding Immunovant’s share is Viking Global Investors LP. It holds Immunovant’s shares valued at 61M.
---
Immunovant Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.46 (69.21% Upside)
$49.46 (69.21% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 57.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
37.75%
12-Months-Change
Fundamentals
Return on Equity
-64.54%
Trailing 12-Months
Asset Growth
67.89%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.
---
IMVT Stock 12 Month Forecast
Average Price Target
$49.46
▲(69.21% Upside)
Technical Analysis
ALX Oncology Holdings
―
Arcutis Biotherapeutics
―
Cabaletta Bio
―
Apellis Pharmaceuticals
―
Best Analysts Covering IMVT
1 Year
1 Year Success Rate
6/9 ratings generated profit
1 Year Average Return
+16.97%
reiterated a buy rating 9 days ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +16.97% per trade.
---